Thijs Cohen Tervaert
Partner @ Inkef
Amsterdam, The Netherlands
Thijs Cohen Tervaert is a Director at INKEF Capital. He Attended Leiden University.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Thijs Cohen Tervaert invests in
Stages Thijs Cohen Tervaert invests in
Countries Thijs Cohen Tervaert invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Biopharma 1 (33%)
- Biotechnology 1 (33%)
- Medical Device 1 (33%)
- Pharmaceutical 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
Country
- Switzerland 1 (33%)
- The Netherlands 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M / Series A / Dec 16, 2025 | ||
| iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $85.7M / Series B / Jun 20, 2024 | ||
| TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $44.2M / Series A / Feb 19, 2022 |
Co-Investors
About Inkef
Inkef is a venture capital firm based in Amsterdam, backing promising early stage companies in Europe. Inkef takes pride in being a patient, long-term investor with the ability to support companies through several rounds of funding. From the early stages of a technology or life science venture, Inkef supports entrepreneurs building their ideas intosuccessful international businesses.Investment areas: Technology and Healthcare
Inkef Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Frank Lansink
Partner
|
|||
|
Thijs Cohen Tervaert
Partner
|
|||
|
Derk Arts
Founder
|
|||
|
Ivan Burkov
Principal
|
|||
Simone Botti
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Thijs Cohen Tervaert invest in?
Thijs Cohen Tervaert invests primarily in Health Care, Biopharma and Biotechnology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Thijs Cohen Tervaert?
Public channels for Thijs Cohen Tervaert include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Thijs Cohen Tervaert last invest?
The most recent investment recorded for Thijs Cohen Tervaert closed in Dec 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
